MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care  Fall

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care Fall

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511.

Sponsored Lunch Symposium
Title: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape
Date: Thursday, September 4, 2025
Time: 11:40 – 1:10 p.m. PDT
Faculty: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott Boynton, DPM, FACFAS
Description: Wound care is constantly evolving, and clinicians must adapt to an ever-changing landscape of patient complexities and clinical challenges. In this dynamic symposium, Drs. Paul Kim, Nicolas Mouawad, and Scott Boynton will discuss advanced treatment approaches that support clinicians in optimizing wound healing across diverse patient populations and present challenging real-world cases.

Accepted Poster Presentations
The Company is pleased to announce that six clinical and scientific posters have been accepted and will be on display in the poster hall.

  • Therapeutic Potential of Amniotic Tissue in Promoting Pigment Restoration During Wound Healing
  • Bovine Extracellular Matrix Particulate Modulates Fibroblast Cellular Activities Supportive of Wound Management
  • Characterization of PURION® Processed Dual Layer Chorion Allograft
  • Amniotic Membrane Allografts promote re-epithelialization in vitro via cJUN Mediated Mechanism
  • Adjunctive Dehydrated Human Amnion Chorion Membrane Usage for Pressure Injuries in the Post-Acute Care Setting
  • Reconstruction Following Mohs Surgery with a Placental Allograft: A Cost-Effectiveness Analysis

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com .

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MDXG
The Conversation (0)
MIMEDX to Participate in Upcoming Investor Conferences

MIMEDX to Participate in Upcoming Investor Conferences

MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 21 st Annual Institutional Investor Conference Wednesday, May 29, 2024 Renaissance Minneapolis Hotel, The Depot... Keep Reading...
MIMEDX Announces First Quarter 2024 Operating and Financial Results

MIMEDX Announces First Quarter 2024 Operating and Financial Results

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024 , at 4:30 PM ET MiMedx Group, Inc. (Nasdaq: MDXG)... Keep Reading...
Satellos Bioscience Inc.

Satellos Bioscience Inc.

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this... Keep Reading...
Vaxcyte Inc.

Vaxcyte Inc.

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Keep Reading...
G6 Materials

G6 Materials

OverviewG6 Materials Corp. (TSXV:GGG,OTCQB:GPHBF) provides high-tech graphene solutions for a variety of commercial, research and military applications at low costs. Through the company’s wholly-owned subsidiary, Graphene Laboratories Inc., G6 Materials currently offers over 100 graphene and... Keep Reading...
G6 Materials Corp Closes $1,001,000 Private Placement

G6 Materials Corp Closes $1,001,000 Private Placement

G6 Materials Corp. (TSXV:GGG) (OTC:GPHBF) (the “Company” or “G6”) is pleased to announce that it has closed a non-brokered private placement and issued 14,300,001 units at a price of $0.07 per unit to raise aggregate proceeds of $1,001,000.07. Each unit consists of one common share and one... Keep Reading...
G6 Materials Corp. Announces Upsize of Private Placement to Raise $1,001,000

G6 Materials Corp. Announces Upsize of Private Placement to Raise $1,001,000

G6 Materials Corp. (the “Company” or “G6”) (TSXV:GGG) (OTC:GPHBF) is pleased to announce its intention to increase the size of its previously announced non-brokered private placement from C$350,000 to $1,001,000. The Company will issue up to 14,300,000 Units for total gross proceeds of up to... Keep Reading...
G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19

G6 Materials Corp. Develops Disinfection Products to Fight the Spread of COVID-19

G6 Materials Corp. (the “Company” or “G6”) (TSXV:GGG) (OTC:GPHBF) is pleased to provide an update from its Research & Development department. The outbreak of the COVID-19 has drastically altered the economic landscape, and G6 management is optimizing the business model to accommodate the new... Keep Reading...

Interactive Chart

Latest Press Releases

Related News